^
    No biomarker
    Germ Cell Tumors
    dactinomycin
    Sensitive: A1 - Approval
    No biomarker
    Germ Cell Tumors
    ifosfamide
    Sensitive: A1 - Approval
    No biomarker
    Germ Cell Tumors
    TI-CE
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    CaT
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    VC
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    GemOx
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    BEP
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    EP
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    VIP
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    VAC
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    VeIP
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    TIP
    Sensitive: A2 - Guideline
    TMB-H
    Germ Cell Tumors
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    paclitaxel + ifosfamide
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    paclitaxel + gemcitabine
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    carboplatin + docetaxel
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    docetaxel
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    etoposide IV
    Sensitive: A2 - Guideline
    No biomarker
    Germ Cell Tumors
    paclitaxel + gemcitabine + oxaliplatin
    Sensitive: A2 - Guideline
    MSI-H/dMMR
    Germ Cell Tumors
    pembrolizumab
    Sensitive: A2 - Guideline
    BRCA1 mutation
    Germ Cell Tumors
    olaparib
    Sensitive: C1 - Off-label
    XPA expression
    Germ Cell Tumors
    cisplatin
    Resistant: C3 – Early Trials
    MTOR mutation
    Germ Cell Tumors
    everolimus
    Sensitive: C3 – Early Trials
    KRAS amplification
    Germ Cell Tumors
    MEK inhibitor
    Sensitive: C3 – Early Trials
    Chr t(22)
    Germ Cell Tumors
    cisplatin + ifosfamide + etoposide oral + mesna
    Sensitive: C4 – Case Studies
    EGFR L858R
    Germ Cell Tumors
    icotinib
    Sensitive: C4 – Case Studies
    BAX underexpression
    Germ Cell Tumors
    cisplatin
    Resistant: C4 – Case Studies
    TP53 mutation
    Germ Cell Tumors
    cisplatin
    Resistant: C4 – Case Studies
    EGFR L858R
    Germ Cell Tumors
    icotinib
    Sensitive: C4 – Case Studies
    MSH6 mutation
    Germ Cell Tumors
    camrelizumab
    Sensitive: C4 – Case Studies
    BRCA2 mutation
    Germ Cell Tumors
    camrelizumab
    Sensitive: C4 – Case Studies
    PMS2 mutation
    Germ Cell Tumors
    camrelizumab
    Sensitive: C4 – Case Studies
    PLAC8 overexpression
    Germ Cell Tumors
    etoposide oral
    Resistant: D – Preclinical
    BRCA1 expression
    Germ Cell Tumors
    olaparib
    Resistant: D – Preclinical
    RAD51C expression
    Germ Cell Tumors
    olaparib
    Resistant: D – Preclinical